Now, a study in Genes & Diseases reports a previously unrecognized epigenetic route through which the iron-responsive protein IRP1 collaborates with the transcription factor ARID3A to suppress ferroptosis and promote chemoresistance. The work links iron sensing to chromatin regulation and identifies a pathway that could be exploited therapeutically.

Across pancreatic cancer specimens, the authors find that both IRP1 and ARID3A are highly expressed and correlate with poor chemotherapy outcomes and unfavorable patient survival. In cell-based functional assays, elevating either protein enhances proliferation and increases resistance to gemcitabine, while silencing IRP1 or ARID3A restores chemosensitivity and suppresses tumor growth in models.

Mechanistically, intracellular iron accumulation drives IRP1 into the nucleus, where it physically associates with ARID3A. Rather than altering transcription solely through classic repression, the IRP1–ARID3A complex remodels chromatin dynamics to reduce accessibility at the cytoglobin (CYGB) promoter. This epigenetic shift suppresses CYGB expression without relying on direct transcriptional shutdown.

CYGB, in turn, plays a role in maintaining redox balance and regulating oxidative stress responses. When CYGB is diminished, pancreatic cancer cells show reduced lipid peroxidation, less reactive oxygen species accumulation, and stronger survival under ferroptosis-inducing conditions. The study connects these biochemical changes directly to the observed drug-resistant phenotype.

Crucially, restoring CYGB or disrupting the IRP1–ARID3A interaction reverses the ferroptosis-resistant state, resensitizing cells to ferroptosis and improving gemcitabine efficacy. In vivo, combining ferroptosis-relevant interventions with suppression of this signaling axis markedly restricts tumor progression.

The findings position the IRP1–ARID3A–CYGB axis as a central determinant of ferroptosis resistance in pancreatic cancer. By uniting iron metabolism, epigenetic control, and regulated cell death, the work offers a mechanistic basis for pairing chemotherapy with ferroptosis-targeting strategies in patients who do not respond to standard treatment.

Subject of Research: Ferroptosis resistance and chemoresistance in pancreatic cancer via IRP1–ARID3A–CYGB epigenetic regulation

Article Title: IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis

News Publication Date:

Web References: http://dx.doi.org/10.1016/j.gendis.2025.101866

References:

Image Credits:

Keywords: pancreatic cancer; ferroptosis; IRP1; ARID3A; CYGB; chemoresistance; epigenetics; iron metabolism; gemcitabine

The team conducted an unprecedented epigenomic analysis on over 1,500 AML patient samples, utilizing ATAC-seq technology to map chromatin accessibility across the genome. This method revealed 16 distinct AML subgroups characterized by unique patterns of open chromatin regions, transcription-factor networks, and super-enhancer landscapes. These epigenetic signatures delineate molecular wiring underlying disease progression, clinical outcomes, and drug sensitivity, independently contributing information beyond what gene mutation profiles alone can provide.

Single-cell RNA and ATAC sequencing validated that these epigenomic subgroups maintain consistent chromatin states throughout leukemic cell populations, underscoring their biological relevance. Intriguingly, many groups did not correlate fully with existing genomic classifications, exposing latent AML diversity invisible to mutation-centric analyses. This discovery broadens our understanding of AML as a disease shaped not only by genetic alterations but also by the epigenomic context that governs gene expression programs.

Clinically, integrating epigenomic data substantially improved risk stratification models traditionally based on somatic mutations. The study identified unexpected vulnerabilities: for example, subsets lacking canonical RAS mutations showed sensitivity to MEK inhibitors, while a subgroup with RUNX1 mutations exhibited susceptibility to ABL inhibitors typically reserved for distinct leukemias. This insight paves the way for re-purposing targeted therapies guided by epigenomic biomarkers, potentially enhancing precision medicine approaches.

The researchers further distilled their findings into a 30-gene expression signature capable of pinpointing high-risk epigenomic subgroups using standard sequencing platforms. This compact biomarker panel aims to facilitate clinical adoption, supporting refined prognosis and tailored treatment selection in routine practice. Beyond AML, the comprehensive multi-omics database generated forms a valuable foundation for cancer epigenomics research, catalyzing discoveries of novel mechanisms and therapeutic targets.

Overall, this study marks a paradigm shift by positioning chromatin state and epigenetic heterogeneity as central determinants of AML biology, prognosis, and therapy response. Moving forward, the team plans to develop cost-efficient diagnostic tools and therapeutic algorithms stratified by epigenomic subgroup, working to embed these advances into everyday clinical use. This landmark research, published in Nature, signals a new era in leukemia precision medicine where genome and epigenome jointly inform patient care.

Subject of Research: People
Article Title: Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
News Publication Date: 8-Jul-2026
Web References: https://www.nature.com/articles/s41586-026-10703-4
References: Ochi, Y., Liew-Littorin, M., Nannya, Y., et al. Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia. Nature (2026). DOI: 10.1038/s41586-026-10703-4
Image Credits: ASHBi/Kyoto University
Keywords: Acute myeloid leukemia, epigenomics, chromatin, ATAC-seq, transcription-factor networks, super-enhancers, precision medicine

Ependymomas are among the most frequently diagnosed brain tumors in children, notorious for their resistance to conventional chemotherapy and the high likelihood of disease relapse. Prior to this study, the molecular mechanisms through which ZFTA-RELA fusions contribute to tumor formation remained elusive. Unlike typical oncogenic proteins that significantly alter chromatin accessibility to activate growth-promoting gene programs, ZFTA-RELA operates differently. The research team observed that chromatin accessibility patterns were largely preserved, suggesting that the fusion protein exploits pre-existing developmental regulatory landscapes rather than establishing new ones.

Stephen Mack, PhD, co-corresponding author and developmental neurobiologist at St. Jude, elaborated: “Our findings defy conventional expectations surrounding oncogenic fusion proteins. The ZFTA-RELA fusion does not engender widespread chromatin remodeling. Instead, it occupies regulatory regions already configured during normal brain development, effectively locking cells in a state akin to developmental limbo.” This unique mode of action points to the fusion protein’s ability to maintain the activation of gene programs that should normally be transient during normal neural maturation.

Central to this mechanism is the mimicry of PLAG/L family proteins by the ZFTA-RELA fusion. PLAG/L proteins are key developmental regulators, which bind discrete DNA sequences to activate gene expression programs essential for early cell differentiation. Normally, these PLAG/L-mediated programs close once the cells reach a mature state. The ZFTA-RELA fusion, however, binds to the same DNA motifs and perpetuates the activity of these early developmental programs, effectively preventing the normal maturation cascade. This pathological persistence of immature gene programs underlies tumor proliferation and resistance to therapy.

Alisha Kardian, a graduate student involved in the study, emphasized the therapeutic implications: “By elucidating how normal cells attenuate PLAG/L chromatin accessibility, we can begin exploring strategies to counteract the oncogenic mimicry exerted by ZFTA-RELA. Targeting this interaction holds promise for novel interventions that push tumor cells out of their arrested state.” This insight suggests that directing therapy towards forcing maturation of tumor cells could bypass resistance mechanisms inherent to immature, proliferative cell states.

Additionally, the investigation uncovered remarkable details regarding tumor cell heterogeneity and clonal dominance within ependymomas harboring ZFTA-RELA fusions. Despite the abnormal activation of multiple developmental pathways, the tumor population stems predominantly from a limited number of ancestral “winner” cells. These dominant clones possess the capability to toggle between diverse developmental gene programs, illustrating the fusion protein’s role in orchestrating a flexible transcriptional landscape conducive to tumor growth.

Dr. Mack pointed out a critical threshold phenomenon: “Our data suggest the existence of a ‘sweet spot’ for ZFTA-RELA expression that drives oncogenic activity. Suboptimal levels of fusion protein fail to sustain proliferative programs, whereas excessive expression proves cytotoxic. This nuance underlines why residual tumor cells—even in minimal numbers—pose a high risk for relapse post therapy.” Such findings spotlight the challenges in completely eradicating tumor clones and stress the need for highly effective, sustained treatments.

Current treatment paradigms for pediatric ependymoma rely heavily on surgical resection and radiotherapy, with chemotherapy often proving ineffective. The revelation of this developmental roadblock imposed by ZFTA-RELA spotlights a critical avenue for innovation. By aiming to pharmacologically or genetically push cells beyond their arrested immature state, therapies could overcome intrinsic resistance and reduce relapse rates, bringing new hope to patients and families affected by this devastating disease.

Kelsey Bertrand, MD, co-corresponding author and oncologist at St. Jude, remarked on the clinical significance: “Ependymomas’ resilience against standard chemotherapy has long impeded successful long-term treatment. This foundational understanding of the ZFTA-RELA fusion’s role in maintaining cell immaturity provides a much-needed direction for future therapeutic development, potentially overcoming these barriers.” The collaborative effort underscores the power of integrative research bridging developmental biology with oncology.

The study’s cohort was a multidisciplinary consortium spanning multiple institutions, including St. Jude Children’s Research Hospital, Baylor College of Medicine, University of Bath, UT Southwestern, Dana-Farber Cancer Institute, University of California San Francisco, and others. Their combined expertise in genomics, neurobiology, cancer biology, and clinical oncology enabled the comprehensive dissection of this complex fusion protein’s function.

Funding support spanned numerous prestigious agencies, including the National Cancer Institute, Department of Defense, National Institutes of Health, National Brain Tumor Society, Alex’s Lemonade Stand Foundation, and many philanthropic organizations supporting pediatric cancer research. This extensive backing reflects the critical importance and promise of the study’s discoveries in addressing childhood brain tumors.

By elucidating the fundamentally novel approach by which the ZFTA-RELA fusion protein sustains pediatric ependymoma cells in a non-mature state, this research breaks new ground. It challenges established models of oncogenic transformation and compels the field to consider developmentally focused therapies that shift tumor cell states as a viable and innovative therapeutic strategy.

Subject of Research: Pediatric ependymoma and oncogenic fusion proteins

Article Title: Fusion oncoprotein ZFTA-RELA locks pediatric ependymoma cells in developmental limbo

News Publication Date: March 25, 2026

Web References:
https://www.stjude.org
https://dx.doi.org/10.1038/s41586-026-10270-8

Image Credits: St. Jude Children’s Research Hospital

Keywords: Pediatric brain tumors, ependymoma, ZFTA-RELA fusion, oncogenic fusion protein, chromatin accessibility, developmental biology, tumor cell heterogeneity, pediatric oncology, fusion oncoprotein mechanisms, cellular differentiation blockade, therapeutic resistance

Researchers have delved into the intricate developmental trajectory starting from bone marrow myeloid progenitors, through circulating monocytes, culminating in the immunosuppressive mo-macs that infiltrate lung tumors. By employing paired transcriptomic and chromatin accessibility analyses in both murine models and human patients with lung cancer, the study captures the dynamic epigenetic and gene expression landscape that shapes this continuum. The scale and precision of this approach illuminate the molecular underpinnings dictating macrophage functionality within cancer.

A striking revelation from the investigation centers on the pivotal transcription factor NRF2 (encoded by Nfe2l2). Unlike its classical roles primarily defined in oxidative stress response, NRF2 emerges here as a master regulator reprogramming myeloid progenitor cells in the bone marrow. Lung tumors orchestrate the priming of chromatin accessibility at NRF2-associated loci, effectively conditioning progenitors to adopt a cytoprotective state. This adaptation enhances the myelopoietic output favoring monocytes that are pre-equipped to support tumor progression rather than immune defense.

This NRF2-driven epigenetic priming operates as a double-edged sword. While it shields progenitor cells from oxidative stress inherent in the tumorous milieu, it concurrently dampens the interferon response pathways critical for antitumor immunity. The paradoxical suppression of immune stimulation facilitates a permissive environment for tumor-supportive macrophage populations to flourish. These myeloid progenitors thus become unwitting allies of cancer in evading immune surveillance.

Further intrigue unfolds as the NRF2 axis activity not only initiates in the bone marrow but also intensifies during the differentiation of monocytes into mo-macs once they infiltrate the TME. This amplification reinforces the cytoprotective and immunosuppressive phenotypes essential for macrophage survival and function amidst the harsh conditions of the tumor niche. The findings suggest an epigenetic “memory” imparted on progenitor cells that is then magnified within tumors to sustain immune evasion.

The functional importance of NRF2 in sustaining tumor-supportive macrophages was rigorously tested through genetic ablation and pharmacological inhibition strategies. Loss of NRF2 activity led to a significant reduction in mo-mac survival and their immunosuppressive capabilities within the TME. Consequently, this shift liberated natural killer (NK) cells and T lymphocytes from suppression, reinvigorating endogenous antitumor immunity. The therapeutic implications hint at re-sensitizing tumors to immune system attack by targeting a heretofore overlooked progenitor pathway.

In addition to reversing local immunosuppression, NRF2 inhibition synergistically enhanced the efficacy of checkpoint blockade immunotherapies, which have revolutionized cancer treatment but remain ineffective in a large subset of patients. The study suggests that curbing dysregulated myelopoiesis can remove a critical roadblock to immune checkpoint success, offering a combinatorial strategy to amplify durable responses in refractory lung cancers.

This research also underscores a broader paradigm shift, emphasizing the importance of earliest myeloid progenitor stages as therapeutic targets. Rather than focusing solely on suppressing established immunosuppressive cells within tumors, reprogramming progenitor epigenetic landscapes at the source could recalibrate the immune composition of the TME long before macrophages acquire their pro-tumorigenic identity. Such early interventions may yield more profound and sustained immunomodulatory benefits.

At a mechanistic level, this study contributes novel insights into how tumor-derived signals remodel hematopoietic compartments distant from the tumor site, demonstrating that cancer orchestrates systemic immune remodeling via epigenetic reconfiguration. The activation of NRF2 as a cytoprotective strategy in progenitors reveals a sophisticated interplay between oxidative stress and immune regulation that tumors exploit for their advantage.

The work also prompts further questions about the specificity and reversibility of NRF2-mediated chromatin priming. Understanding whether these epigenetic changes can be durably reset and how they interact with other transcriptional circuits in myeloid lineages will deepen our comprehension of tumor-immune coevolution. Additionally, delineating whether similar mechanisms operate in other solid tumors could expand the scope of NRF2-targeted therapies.

In conclusion, this illuminating study places NRF2-driven myeloid progenitor dysregulation at the heart of tumor-associated immunosuppression. By mapping the epigenetic and transcriptional alterations from bone marrow progenitors through to tumor-infiltrating macrophages, the researchers reveal a targetable vulnerability capable of reshaping the TME. These findings offer a promising pathway to reprogram immune suppression and enhance the potency of existing immunotherapies, holding transformative potential for lung cancer treatment.

As clinical translation advances, targeting the NRF2 pathway could serve as a dual-pronged approach—protecting progenitor cell integrity while dismantling tumor-favoring immune adaptations. This study not only advances our molecular understanding of tumor immunology but also ignites hope for developing strategies that reinvigorate the immune system’s capacity to combat cancer effectively.

Subject of Research:
Myeloid progenitor dysregulation and its role in fostering immunosuppressive monocyte-derived macrophages within the lung tumor microenvironment.

Article Title:
Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours.

Article References:
Hegde, S., Giotti, B., Soong, B.Y. et al. Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours. Nature (2025). https://doi.org/10.1038/s41586-025-09493-y

Image Credits: AI Generated

One pivotal study sheds light on the evolutionary processes that propel pancreatic cancer, a notoriously aggressive type of cancer characterized by its remarkable heterogeneity. The research team, including prominent scientists like Dr. Luigi Perelli and Dr. Giannicola Genovese, utilized genetically engineered models to delve into the cellular transformations associated with epithelial-to-mesenchymal transition (EMT). The findings revealed that EMT enables the malignant evolution of epithelial tumors, primarily by enhancing chromatin accessibility and genomic instability. This malleable state increases the variability within tumors, further complicating treatment outcomes. Understanding the restricted evolutionary pathways in cells undergoing EMT provides a framework for devising targeted therapies aimed at overcoming tumor heterogeneity.

In a significant breakthrough concerning immunotherapy for advanced kidney cancer, researchers have demonstrated that surgical intervention may enhance the efficacy of immune checkpoint therapy. Under the direction of Dr. Padmanee Sharma and her colleagues at the James P. Allison Institute™, the study examined 104 patients with clear cell renal cell carcinoma. Results indicated that patients who underwent surgery in conjunction with immunotherapy experienced a median overall survival of 54.7 months, highlighting the potential of surgical resection to alleviate immunosuppression and augment antitumor immune responses. This research suggests that surgical treatment could serve as a critical adjunct to current immunotherapeutic approaches, offering patients improved survival outcomes.

In the context of breast cancer, a study has identified an epigenetic biomarker linked to metastatic relapse. Dr. Jayanta Mondal and Dr. Jason Huse conducted an extensive investigation using in vivo epigenetic screens on breast cancer models. They pinpointed Brd7, a key protein involved in chromatin remodeling, as a critical mediator in cancer dormancy at secondary sites. The loss of Brd7 was associated with the reactivation of dormant metastatic cells, leading to the formation of tumors in the lungs by creating a favorable immune environment that promotes tumor growth. This discovery not only underscores the importance of epigenetic regulation in metastasis but also positions Brd7 as a potential prognostic biomarker, which may assist in predicting the likelihood of relapse in breast cancer patients.

Another innovative development stems from the intersection of bioinformatics and cancer proteomics. Led by Dr. Han Liang, researchers created a highly customizable bioinformatics chatbot named DrBioRight 2.0, aimed at analyzing large-scale proteomic data efficiently. This platform empowers researchers to navigate vast datasets derived from initiatives like The Cancer Genome Atlas, making sophisticated bioinformatics tools more accessible to those working in the field. The chatbot functions by utilizing natural language processing, significantly enhancing the analytical capabilities of researchers studying proteomic changes in cancer, a critical adjunct to genomic analysis.

The management of acute myeloid leukemia (AML) has seen promising results from a Phase II trial examining the efficacy of a novel combination therapy involving fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) alongside venetoclax. Conducted under the guidance of Dr. Courtney DiNardo, the study reported a remarkable overall response rate of 97% among newly diagnosed AML patients. Furthermore, 95% of patients achieved undetectable measurable residual disease status, indicating effective disease control. This combination therapy not only demonstrated favorable outcomes across various risk profiles but also highlighted a potential strategy for improving treatment options for high-risk AML patients.

The exploration of biomarkers in HPV-positive anal cancer emphasizes the need for improved treatment strategies for patients facing unresectable and metastatic disease. Dr. Van Morris led a Phase II trial evaluating the effectiveness of atezolizumab and bevacizumab in a small cohort of patients. While the combination therapy did not exceed the efficacy of traditional chemotherapy, researchers identified promising chromosomal and transcriptomic markers associated with enhanced survival in patients undergoing immunotherapy. These insights contribute to a deeper understanding of the tumor-immune microenvironment and may inform the development of more effective therapeutic regimens in the future.

As MD Anderson continues to push the boundaries of cancer research, the integration of genomics and epigenetics increasingly plays a crucial role in understanding the complexities of cancer biology. The identification of genetic and epigenetic alterations lays the groundwork for personalized medicine approaches that target individual tumor profiles, offering new avenues for treatment. Continued research in these areas may unveil novel therapeutic targets and improve outcomes for patients battling the myriad challenges posed by cancer.

In summary, the groundbreaking advancements emerging from the University of Texas MD Anderson Cancer Center underscore the institution’s commitment to transformative cancer research. By combining innovative laboratory techniques with advanced clinical trials, researchers are making strides towards enhancing patient outcomes and providing more effective treatment strategies. As the scientific community builds on these findings, the hope of achieving more precise and effective cancer therapies becomes increasingly tangible, promising a brighter future for patients around the world.

The confluence of cutting-edge technology and rigorous scientific inquiry is reshaping the landscape of cancer treatment. As the field evolves, the synergy between scientists and clinicians remains fundamental to translating research discoveries into clinical applications. The collaborative efforts at MD Anderson exemplify the power of interdisciplinary research in propelling forward the fight against cancer, inspiring hope for patients and their families in the face of this relentless disease.

Medical research is inherently an ongoing journey filled with continuous learning and adaptation. The discoveries being made not only enhance our understanding of cancer biology but also equip healthcare professionals with the knowledge necessary to refine treatment paradigms. This vital work highlights that the battle against cancer is not fought in isolation but rather through the deep ties that bind the scientific community and patient care arena together, united in the pursuit of effective, life-saving therapies.

The commitment of researchers to push the envelope of knowledge ensures that the future of cancer treatment will be one of innovation and hope. As these studies elucidate the underpinnings of cancer’s complexity, they signal the advent of more effective, personalized therapy modalities. With sustained research efforts and collaborative spirit, the ongoing crusade against cancer continues to pave the pathway to breakthroughs that will change lives for countless individuals battling this disease.

The intertwining of research and clinical application epitomizes the essential mission driving MD Anderson Cancer Center. Through unwavering dedication to excellence and innovation, the institution remains at the forefront of cancer research, steadfast in its goal to translate breakthroughs into tangible benefits for patients. As novel strategies evolve and our understanding deepens, the prospects for achieving better outcomes in cancer care become increasingly promising.

Subject of Research: Insights into cancer biology and treatment advancements
Article Title: Recent Advances in Cancer Research: Pioneering Studies from MD Anderson
News Publication Date: October 2023
Web References: MD Anderson Research Highlights
References: Nature, Nature Communications, Clinical Cancer Research, Leukemia
Image Credits: University of Texas MD Anderson Cancer Center

Keywords: Cancer research, pancreatic cancer, immunotherapy, chronic myeloid leukemia, HPV-positive anal cancer, epigenetics, biomarker discovery, surgical intervention, combination therapy, bioinformatics, tumor heterogeneity, metastasis.